Has Gabriel Pilar, MD received payments from drug or device companies?

Yes. Drug and device makers reported $626 in general payments to Gabriel Pilar, MD across 29 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Gabriel Pilar, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Gabriel Pilar, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Gabriel Pilar, MD

Neurology · West Reading, PANPI 1194087726

Payments from drug & device makers

$626in general payments, 2019–2025

Across 29 payments — averaging $21.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

AbbVie$152
MDD US Operations, LLC$87
Supernus Pharmaceuticals, Inc.$47
Greenwich Biosciences, Inc.$46
EMD Serono, Inc.$46
Boston Scientific$37
plus $211 from 12 others

What the payments were for

Food & beverage$61598%
Education$112%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
AbbVie(2 entities)	6	$152
MDD US Operations, LLC	1	$87
Supernus Pharmaceuticals, Inc.	2	$47
Greenwich Biosciences, Inc.	2	$46
EMD Serono, Inc.	3	$46
Boston Scientific	1	$37
Adamas Pharmaceuticals, Inc.	2	$30
Neurocrine Biosciences, Inc.	2	$27
Amgen	1	$23
Bausch Health US, LLC	1	$22
Genentech USA, Inc.	1	$17
E.r. Squibb & Sons, L.L.C.	1	$16
Arbor Pharmaceuticals, Inc.	1	$15
Jazz Pharmaceuticals Inc.	1	$14
Novartis	1	$13
Acadia Pharmaceuticals Inc	1	$11
Strongbridge US Inc.	1	$11
Akcea Therapeutics, Inc.	1	$11

How this compares

$626 in reported general payments places this provider in the 40th percentile of 941 neurology providers in Pennsylvania.

See all neurology providers in Pennsylvania →

Medicare billing

Part B allowed, 2024

$84,208

Medicare patients

272

Services billed

957

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
GammakedImmune Globul G/Gly/Iga Avg 46	26	$902,462
Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov50	60	$764,080
RystiggoRozanolixizumab-Noli	14	$716,682
FirdapseAmifampridine Phosphate	11	$688,917
OctagamImmun Globg(Igg)/Malt/Iga Ov50	25	$387,457
HizentraImmun Glob G(Igg)/Pro/Iga 0-50	23	$358,590
Gamunex-CImmune Globul G/Gly/Iga Avg 46	31	$169,075
Nurtec OdtRimegepant Sulfate	16	$16,443
UbrelvyUbrogepant	18	$15,812
Mycophenolate Mofetil	47	$9,767
Pyridostigmine Bromide	75	$7,199
Pregabalin	149	$5,188
Levetiracetam	71	$3,676
Gabapentin	192	$3,616
Lacosamide	50	$3,047

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

Company	Paid to this provider	Part D cost of their drugs
AbbVieUbrelvy	$152	$15,81218 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 941 neurology providers in Pennsylvania.